433results about "Protease inhibitors" patented technology

The present application relates to a fibroblast activation protein ligand and a use thereof, and in particular to a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound, and a use thereof in diagnosis or treatment of diseases related to a fibroblast activation protein, such as tumors or cancers.

The invention relates to the technical field of coating surface preparation, in particular to an anticoagulant coating based on novel tick-derived anticoagulant protein Qinghaenin and a preparation method of the anticoagulant coating. The functional layer of the anticoagulant coating comprises the following components: anticoagulant protein Qinghaenin or a functional peptide fragment Qinghaenin 167-192 of the anticoagulant protein Qinghaenin, wherein the amino acid sequence of the functional peptide fragment is as shown in SEQ ID NO. 2. The preparation method of the anticoagulant coating comprises the following steps: by using a polydopamine coating as a substrate layer, covalently grafting through an amido bond, immobilizing anticoagulant protein Qinghaenin capable of inhibiting FXII factor activation or a functional peptide fragment Qinghaenin 167-192 thereof on the surface of a medical polymer material, and successfully constructing a novel anticoagulant coating. Compared with an unmodified medical polymer material, the modified coating can significantly enhance the hydrophilic performance of the material and inhibit platelet adhesion and activation, finally effectively prolongs the in-vitro blood coagulation time, and shows excellent anticoagulation performance.

The invention discloses a preparation method of an ulinastatin crude product, which comprises the following steps: a, adsorbing urine of healthy adults by using macroporous adsorption resin, and then desorbing by using a salt solution to obtain an eluent; b, carrying out ultrafiltration concentration on the obtained eluent to obtain a first concentrated solution; c, purifying and eluting the concentrated solution obtained in the step b by using a lectin affinity chromatography column, and collecting a liquid phase; d, performing ultrafiltration concentration on the obtained liquid phase to obtain a second concentrated solution; and e, salting out the second concentrated solution, and filtering to obtain the ulinastatin crude product. The ulinastatin prepared by the preparation method disclosed by the invention is high in specific activity and long in shelf life.

The disclosure provides compositions and methods for the detection of renal disease and periodontal disease in mammals.

The invention belongs to the field of medicines, and discloses application of a protein polymer in preparation of a medicine for treating autism. The inventor finds that a protein polymer generated after mesenchymal stem cells are stimulated by a stress environment, such as ultraviolet radiation, has a certain treatment effect on autism, and provides possibility for treatment of autism.

The invention belongs to the technical field of biology, and particularly discloses a high-temperature-resistant antibacterial protein Cystatin B sourced from marine fish as well as a preparation method and application of the high-temperature-resistant antibacterial protein Cystatin B. The high-temperature-resistant antibacterial protein Cystatin B is derived from pomfret, and the amino acid sequence of the high-temperature-resistant antibacterial protein Cystatin B is as shown in SEQ ID NO. 1; the nucleotide sequence of the gene for coding the high-temperature-resistant antibacterial protein Cystatin B is as shown in SEQ ID NO.2, and the sequences of primers adopted for cloning the gene are as shown in SEQ ID NO.3-4. The high-temperature-resistant antibacterial protein Cystatin B has a remarkable antibacterial effect on gram-negative bacteria such as escherichia coli, vibrio parahaemolyticus and edwardsiella tarda as well as gram-positive bacteria such as staphylococcus aureus; and after being treated at the temperature of 100 DEG C, the antibacterial agent still can keep relatively high antibacterial activity. The antibacterial protein is simple in preparation method, can replace traditional antibiotics, and can quickly and efficiently prevent and treat various common bacterial diseases in aquaculture.

The invention discloses a medicago sativa MsKTI3 gene and application of the medicago sativa MsKTI3 gene in improving the salt tolerance of plants, a candidate gene MsKTI3 related to the salt tolerance of medicago sativa is screened out through transcriptome sequencing analysis, the MsKTI3 is cloned, the medicago sativa and arabidopsis thaliana are over-expressed, and the functions of the gene are identified. According to the invention, a foundation is laid for deeply researching functions and a salt-tolerant regulation mechanism of MsKTI3, and a candidate gene resource is also provided for improving salt-tolerant molecules of alfalfa.

The invention belongs to the field of biological medicines, and discloses an application of a protein polymer in preparation of a medicine for treating Alzheimer's disease, a production process of the protein polymer comprises the following steps: S1) using ultraviolet irradiation to stimulate mesenchymal stem cells and culturing; and S2) splitting the mesenchymal stem cells, separating and purifying to obtain the protein polymer. According to the present invention, the mesenchymal stem cells are stimulated to express the protein with the nerve repair function through the ultraviolet irradiation stress mode, and the protein polymer is obtained through further separation and purification, such that the protein polymer can be adapted to diversified application modes, can improve the abnormal conditions of the Alzheimer's disease related biomarkers, and can provide the significant treatment effect on the Alzheimer's disease.

A composition comprising, for example, chemically modified RNA (cmRNA) encoding CST6 or a polypeptide with at least 80% amino acid sequence identity thereto, and methods of making and using the cmRNA, are provided.

Provided herein are methods for producing natural and reconstructed hyaluronic acid (HA) complexes containing pentraxin-3 (PTX3) and heavy chain 1 (HC1) of inter-alpha inhibitor (IαI). Provided are compositions containing the complexes and methods of treatment using the complexes. Also provided are combinations and kits for implementing the methods.

The present invention relates to a fusion protein comprising a main protein and one or more extension peptides, wherein the amino acid sequence of the main protein is identical or similar to the amino acid sequence of a mammalian protein or a fragment thereof, and the extension peptides comprise a cluster of O-glycosylated amino acids. The extension peptide is identical to a non-repeated sequence of a mammalian protein and / or is identical or similar to SEQ ID NO:1. The main protein is preferably VWF. The fusion protein has an increased half-life compared to the main protein and can be used to increase the half-life of a binding partner, such as FVIII. The invention further relates to complexes formed by the fusion proteins, polynucleotides encoding the fusion proteins, and vectors and host cells containing the polynucleotides. [Selected Figure] Figure 1

Disclosed herein are topical compositions for treating wounds. The topically compositions include a Serp-1 polypeptide or a nucleic acid encoding a Serp-1 polypeptide. Also disclosed are methods of treating a wound in subject. The methods include administering a topical formulation that includes a Serp-1 polypeptide or a nucleic acid encoding a Serp-1 polypeptide to the wound.

The invention belongs to the field of biological medicines, and discloses an application of a protein polymer in preparation of a medicine for treating spinal cerebellar ataxia disease, a production process of the protein polymer comprises the following steps: S1) using ultraviolet irradiation to stimulate mesenchymal stem cells and culturing; and S2) splitting the mesenchymal stem cells, separating and purifying to obtain the protein polymer. An ultraviolet irradiation stress mode is adopted, mesenchymal stem cells are stimulated to express protein with a neural repair function, the protein polymer is obtained through further separation and purification, the cell gene expression pathway is regulated, the cell stress state is relieved, the cells are promoted to recover normal forms and functions, meanwhile, the preparation mode is relatively simple, and the preparation method is suitable for large-scale production. And quality and yield monitoring is facilitated, and the method can be adapted to diversified application modes.

The invention discloses application of a rice brown planthopper resistant gene OsCYT2 in rice brown planthopper resistance, and relates to the technical field of brown planthopper resistant transgenic rice. According to the invention, through agrobacterium-mediated genetic transformation, the OsCYT2 gene is transferred into an insect-susceptible rice variety Nipponbare, and the resistance of a plant over-expressed with the OsCYT2 gene to brown planthopper is enhanced. After the brown planthopper eats the transgenic plant, the survival rate of the brown planthopper is reduced, the weight gain of the brown planthopper is reduced, and the amount of secreted honeydew is reduced. The new insect-resistant function of the gene OsCYT2 found by the invention has reference significance for researching gene molecular functions and breeding.

The invention provides a chemical synthesis method of a TIMP2 protein N-terminal structural domain. An amino acid sequence of an N-terminal structural domain of TIMP2 protein is divided into four segments, the four segments are synthesized by a solid-phase polypeptide synthesis method, full-length linear polypeptide is obtained through natural chemical connection, sulfur removal and sulfydryl removal and acetamino methyl removal, finally impurities in a system are removed, the full-length linear polypeptide is dropwise added into a refolding reaction system, oxidation and refolding reactions are carried out, and the TIMP2 protein is obtained. A target product is obtained. The N-TIMP2 of the N-terminal structural domain of the TIMP2 retains the inhibitory activity of the TIMP2 on the MMP14, the N-TIMP2 obtained through chemical total synthesis can introduce non-natural amino acid to any site in the sequence or perform specific modification or mutation in the synthesis process, an effective tool is provided for researching the specific action mechanism of the N-TIMP2 and the MMP14, and a foundation is further laid for research and development of the MMP14 inhibitor.

Aspects of the disclosure relate to compositions and methods for treating one or more inflammatory bowel diseases ("IBDs"), such as ulcerative colitis ("UC") and / or Crohn's disease. Some embodiments relate to a pharmaceutical dosage form comprising a core comprising an inhibitor of a protease (e.g., a bacterial protease) and a controlled release coating applied to an exterior surface of the core. In some cases, the protease inhibitor is a gliptin or a pharmaceutically acceptable salt thereof. In some cases, the controlled release coating is configured to release the protease inhibitor in the large intestine (e.g., colon) and / or small intestine of a subject to whom the pharmaceutical dosage form is administered. Some embodiments relate to methods of treating one or more IBDs comprising delivering a therapeutically effective amount of an inhibitor of a protease (e.g., a bacterial protease) to the large intestine (e.g., colon) and / or small intestine of a subject.

Urinastatin glycoforms, urinastatin fusion polypeptides, and related compositions, mixtures, and methods of use, including methods of recombinantly producing and treating diseases, are provided. Embodiments of the present disclosure include an isolated mature urinastatin polypeptide comprising: (i) an O-linked glycosylation site modified with residues Glu-Gly-Ser-Gly (SEQ ID NO: 10) to reduce glycosylation at the O-linked glycosylation site; (ii) an N-linked glycan at residue N45; and (iii) an O-linked glycan at residue T17, a residue defined by SEQ ID NO: 2 or 4, wherein the urinastatin polypeptide has at least one urinastatin activity.

The present invention relates to peptide comprising the amino acid sequence SEQ ID NO :1, provided that said peptide does not consist in SEQ ID NO: 2, or SEQ ID NO: 3 or any variant thereof having at least 36% identity with SEQ ID NO: 1 or SEQ ID NO: 3, provided that the underlined cysteines (C) in SEQ ID NO: 1 are conserved, and that the variant does not contain another cysteine, and that said variant retains the ability to bind and / or inhibit a BMP-1 / tolloid-like protease or BTP. The use of the peptide in therapy is also disclosed.

Provided are modified virus-like particles (VLPs) of paramyxoviruses, compositions containing them, methods of using the VLPs for delivery of any particular protein of interest to any of a variety of cells, kits that contain expression vectors for making, using and detecting VLPs, and methods for screening for anti-viral compounds using the VLPs. The modified VLPs contain a contiguous recombinant polypeptide that contains i) all or a segment of a C-terminal domain of a paramyxovirus nucleocapsid protein and ii) a polypeptide sequence of a distinct protein. Non-covalent complexes of paramyxovirus M protein and fusion proteins that contain a C-terminal domain of a paramyxovirus nucleocapsid protein and a polypeptide sequence of a distinct protein are provided, as are non-covalent complexes of cells, and cell receptors, with modified VLPs.

Provided herein are compositions and methods for improved generation of SC-β cells in vitro, among others. Provided are novel preparations and differentiation methods that result in SC islet clusters with advantageous characteristics such as higher cell yield and recovery rate, increased number and relative percentage of SC-β cells, enhanced stability and shelf life of SC-β cells, reduced size and increased uniformity, improved function of SC-β cells in vitro, and improved survival rate, function, and reduced immunogenicity after transplantation. The compositions and methods of the present disclosure can be used in the production of SC islets for human therapeutic applications.

The present disclosure relates generally to methods of preventing or inhibiting neutrophil extracellular trap (NET) formation and methods of treating a disease or disorder associated with NET formation in a subject.

Provided herein are methods of suppressing pathogenic mutations using a programmable base editor system, and specifically, compositions comprising a polynucleotide programmable nucleotide binding domain and a nucleoside base editing domain along with a base editor of a guide polynucleotide, and methods of using the base editor. Also provided herein are base editor systems for editing nucleoside bases of a target nucleotide sequence.

The invention relates to the technical field of genetic engineering, in particular to a construction method and culture of a recombinant hirudin expression vector with algae as chassis cells. An endogenous promoter beta2-tubulin and an RBCS2 intron sequence form a key starting element, the key starting element is linked with a Hygromycin resistance gene, a 2A peptide self-cleavage sequence is added between a recombinant hirudin gene and the Hygromycin resistance gene, and the tail end is connected with an HA tag to construct the algae expression vector. In order to improve the safety and synthesis yield of the recombinant hirudin and reduce the production cost, the invention successfully constructs an algae expression vector for expressing the recombinant hirudin; the expression vector can significantly improve the activity and yield of recombinant hirudin.

The invention relates to a method for preserving or re-conditioning a transplant by administering recombinant alpha1-antitrypsin (AAT) protein or fragment thereof, expressed in a genetically modified yeast, to said transplant during ex vivo normothermic perfusion prior to transplantation in a subject. Another aspect of the invention relates to a method for preventing and / or reducing ischemic-reperfusion injury (IRI) of a transplant by administering recombinant alpha1-antitrypsin (AAT) protein or a fragment thereof, expressed in a genetically modified yeast, during ex vivo normothermic perfusion of the transplant prior to transplantation in a subject. A further aspect of the invention relates to a preserved transplant, obtainable by the methods of the invention. A further aspect of the invention relates to a perfusate or kit for preserving a transplant, wherein said perfusate comprises AAT or a fragment thereof expressed in a genetically modified yeast.

The present invention provides a novel antigen for soy allergy, a method and kit for diagnosing soy allergy, a pharmaceutical composition containing the antigen, soybeans or soybean products from which the antigen has been removed, and a tester for determining the presence or absence of soybean antigen in a target object. [Solution] The diagnostic kit of the present invention comprises at least one of the proteins identified as (1) to (8), or at least one of the proteins identified as (1α) to (55α).

The specification relates to a method of manufacturing a diabetic foot patient-specific skin regeneration sheet, and a diabetic foot patient-specific skin regeneration sheet.

The present application relates to the field of biomedical detection, specifically to a SPINK1 specific ELISA detection kit for aging detection, the kit contains polyclonal antibodies specific to SPINK1 protein and a color developing reaction system for assisting detection; the kit is also configured with E. coli derived recombinant SPINK1 protein with a purity of more than 99% as a standard for concentration calibration; the specific reagent list supplied in the kit includes horseradish peroxidase labeled antibody, blocking solution, washing buffer, the color developing reaction system is composed of 3,3',5,5'-tetramethylbenzidine solution, and the termination solution for interrupting the color developing chemical reaction is independently packaged. Through prokaryotic expression technology and targeted optimization of core induction conditions, combined with protein affinity chromatography purification process based on imidazole elution mechanism, the present application successfully realizes high-efficiency soluble expression of SPINK1 protein in E. coli vector and obtains recombinant protein with a purity of more than 99%.

Provided is a technology for substituting egg white in a food product. Serpins derived from plants or fungi are utilized to substitute egg white in a food product.